Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: A chart review study Meeting Abstract


Authors: Gordan, L.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; Reitan, J.; Milkovich, G.; Kaila, S.; Davies, F.; Usmani, S.
Abstract Title: Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: A chart review study
Meeting Title: 20th Annual Meeting and Exposition of the International Myeloma Society
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 23
Issue: Suppl. 2
Meeting Dates: 2023 Sep 27-30
Meeting Location: Athens, Greece
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2023-09-01
Start Page: S98
Language: English
ACCESSION: WOS:001079705400167
PROVIDER: wos
DOI: 10.1016/S2152-2650(23)01733-0
Notes: Meeting Abstract: P-115 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Carlyn Rose Tan
    130 Tan
  2. Saad Zafar Usmani
    296 Usmani